Therefore, as anthracycline chemotherapy has long been the standard of care for younger patients with AML (85), these data combined led us to hypothesize that chemotherapy-induced STING activation in macrophages may enhance the anti-AML effects of CD47 inhibition. This evidence concerns the gene CD47 and acute myeloid leukemia.